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Introduction
Atherogenic dyslipidemia, characterized by high triglyc-
erides (TG) and low high density lipoprotein (HDL)-c-
holesterol levels, is a feature of patients with insulin
resistance, obesity, and type 2 diabetes (T2D) [1] and plays
a major role in shaping the risk of cardiovascular disease.
Both TG and HDL-cholesterol serum concentrations are
under the control of both environmental factors and up to
95 genetic loci, unraveled by a very large genome-wide
association study (GWAs) in approximately 100,000 indi-
viduals [2]. Among these loci is GALNT2, which encode
for ppGal-NAc-T2, involved in O-linked glycosylation.
Similarly, studies in rodents have shown that liver GALNT2
expression modulates HDL-cholesterol concentrations [2].
Based on such studies, it is conceivable that GALNT2
expression changes play a role on TG and/or HDL-c-
holesterol levels. To gain further insights about this
hypothesis, GALNT2 expression was measured in
peripheral white blood cells (PWBC), from 224 individuals
with a wide range of TG and HDL-cholesterol levels, as
well as other metabolic parameters and clinical conditions.
Materials and methods
Ethics Statement
Study design and informed consent procedures were
approved by the local Institutional Ethic Committee of
‘‘Casa Sollievo della Sofferenza’’ Institute (N4080/08, 4/
8/2009) and performed according to the Helsinki Decla-
ration. All participants gave written informed consent.
Subjects
Fasting blood samples were obtained after overnight rest
from 130 non-diabetic individuals (i.e., blood donors) and
94 patients with T2D, recruited at the IRCCS ‘‘Casa Sol-
lievodella Sofferenza’’ (S. Giovanni Rotondo, Gargano,
Italy), as a part of an ongoing project on the genetics of
T2D and its chronic complications. Anthropometric and
clinical features of study subjects were obtained as previ-
ously described [3]. Obesity was defined as body mass
index (BMI) C28 kg/m2. Impaired fasting glucose (IFG)
and diabetes were defined as fasting glucose levels of
100–125 and C126 mg/dl, respectively, after an overnight
fast according to ADA 2003 criteria. At variance with
patients with T2D who were mostly on anti-hyperglycemic
treatments (see ‘‘Results’’ section), IFG individuals
(n = 13) were not; so, in adjusted and/or stratified analy-
ses, they were grouped together with normoglycemic
individuals and then defined as non-diabetic. The insulin
resistance index homeostasis model assessment (HOMAIR)
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was calculated as fasting serum insulin (mU/l) 9 fasting
plasma glucose (mmol/l)/22.5.
Statistical analyses
Relationships between variables were evaluated by uni-
variate or multivariate analysis, as appropriate, by SPSS 13
software. Since TG levels were not normally distributed,
they were log transformed and then used for subsequent
analyses. Data are presented as mean ± SD. A p value less
than 0.05 was considered as significant. Our sample size
had more than 99 % power to detect an association at a
p value of 0.001 between GALNT2 expression and TG
levels similar to that reported between TG levels and
expression of several other genes in PWBC [4].
RNA extraction, cDNA synthesis, and gene
expression analysis from PWBC
Total RNA extraction, cDNA synthesis, and GALNT2
expression were performed as elsewhere reported [3, 5].
Results
Subjects
Table 1 shows clinical features of study subjects. It is of
note that they were characterized by a wide range of both
TG and HDL-cholesterol levels, our outcomes of interest.
Moreover, study individuals showed a wide range of BMI,
excess of adiposity (48.7 % being obese), and glucose
homeostasis (5.8 % with IFG and 42 % with T2D).
Patients with T2D were mostly treated with anti-hyper-
glycemic, anti-dyslipidemic (mostly statins), and anti-hy-
pertensive therapies (Table 1). None of non-diabetic
individuals was chronically treated with any drug. As
expected, TG and HDL-cholesterol levels were strongly
and inversely correlated (r = -0.51, p = 2.6 9 10-16,
Fig. 1a). This association was still significant (p =
8.4 9 10-15) after adjusting for age, gender, and metabolic
status as defined by the following conditions: non-obese
non-diabetic (n = 84), obese non-diabetic (n = 46), and
diabetic (n = 94) individuals.
GALNT2 mRNA expression in PWBC and lipid
levels
In all subjects, GALNT2 mRNA levels were strongly and
inversely associated with serum TG concentrations
(r = -0.22, p = 0.001, Fig. 1b). A significant, though less
pronounced, direct association was observed between
GALNT2 mRNA and HDL-cholesterol levels (r = 0.14,
p = 0.042). In a model comprising both TG and HDL-
cholesterol, GALNT2 expression was associated with TG
(p = 0.008), but not with HDL-cholesterol (p = 0.68)
concentrations. This association was unaffected by age,
gender, and metabolic status (p = 4.3 9 10-4).
To address whether insulin resistance mediated the
observed association, we took advantage of HOMAIR
values available in the 130 non-diabetic individuals. In this
subgroup, the association between GALNT2 expression and
serum TG was still significant after adjusting for HOMAIR
(p = 0.028). Of note, GALNT2 mRNA levels were not
Table 1 Clinical features of
study subjects
Sex (M/F) 156/68
Age (years) 48.6 ± 12.3 (21–80)
BMI (Kg/m2) 28.8 ± 5.4 (20.4–52.5)
HDL-cholesterol (mg/dl) 48.9 ± 14.8 (21–108)
Triglycerides (mg/dl) 146.7 ± 98.7 (28–767)
Obesity (yes/no) 140/84
IFG (yes/no) 13/211
Diabetes (yes/no) 94/130
Anti-hyperglycemic treatment in diabetic patients
Diet only 5
OAD 46
Insulin ± OAD 43
Anti-dyslipidemic treatment in diabetic patients (yes/no) 72/22
Anti-hypertensive treatment in diabetic patients (yes/no) 67/27
Continuous variables were reported as mean ± SD and range in parentheses, whereas categorical variables
as total number
M males, F females, BMI body mass index, Obesity BMI C 28 kg/m2, IFG Impaired Fasting Glucose (i.e.,
fasting glucose 100–125 mg/dl), Diabetes fasting glucose C126 mg/dl, OAD oral anti-diabetes drugs
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correlated with HOMAIR values (p = 0.53). In all, these
results speak against a role of insulin resistance in the
relationship between GALNT2 and TG.
Among diabetic patients, the association between
GALNT2 and TG levels was still significant when the
presence of anti-dyslipidemic treatment was considered as
a covariate (p = 0.007).
Discussion
This study clearly shows that GALNT2 expression in
human circulating blood cells is strongly associated with
serum TG levels in a large sample of individuals with a
wide range of metabolic features, such as lipid levels,
adiposity measures, and glucose homeostasis. This corre-
lation was independent of several possible confounders,
including gender, age, obesity, and diabetes; also insulin
resistance in non-diabetic individuals and anti-dyslipi-
demic treatment in diabetic individuals did not affect the
observed association. Although, by their intrinsic nature,
association studies cannot inform about cause–effect rela-
tionships, our present finding reinforces previous data from
GWAs, pointing GALNT2 as a direct modulator of TG
levels in humans [2]. In contrast, no independent associa-
tion was observed between GALNT2 mRNA and HDL-
cholesterol levels. This latter finding, somehow at variance
with studies on liver-specific GALNT2 changes in rodents
[2], speaks against a direct role of GALNT2 expression on
HDL-cholesterol in humans.
The correlation between GALNT2 expression and TG
levels was similarly observable among non-diabetic and
diabetic individuals, thus suggesting that neither hyper-
glycemia nor diabetes-related therapies do interfere with it.
This indicates that the relationship between GALNT2 and
TG concentrations does not belong to the same patho-
physiological pathway linking GALNT2 to hyperglycemia
observed in humans [3] and rodents [6].
As a limitation of our study, we acknowledge that at this
present stage it is not known whether GALNT2 protein
expression reflects that of GALNT2 mRNA and do mirror
their relationship with serum TG. Unfortunately, since
protein lysates were not obtainable from our specimens, no
such data were available.
As an additional limitation of our study, we acknowl-
edge that, although PWBC are an easily obtainable cell
model widely used for studying gene expression changes in
insulin resistance and related abnormalities [5, 7–9], they
are not involved in lipid metabolism, thus leaving open the
question whether or not our data can be translated into
pathophysiological mechanisms controlling serum triglyc-
erides levels. Thus, present data have to be considered as a
preliminary, hypothesis generating, finding that needs to be
deeper addressed by additional studies in cells responsible
of lipid metabolism, including hepatocytes and adipocytes.
In conclusion, our data suggest a role of GALNT2
expression changes on serum TG and, taken together with
previous genetic findings [2], reinforce the hypothesis that
GALNT2 plays a role on lipid levels and possibly athero-
genic dyslipidemia.
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Fig. 1 a Association between plasma TG and HDL-cholesterol
levels. TG and HDL-cholesterol levels were inversely and signif-
icantly correlated in 224 individuals (r = -0.51, p = 2.6 9 10-16).
b Association between plasma TG and GALNT2. GALNT2 mRNA
expression in PWBC was inversely and significantly correlated with
plasma TG levels (r = -0.22, p = 0.001)
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